<div id="readability-page-1"><p><span>Organon &amp; Co. (NYSE:OGN - Get Free Report)</span> was upgraded by Barclays to a &#34;strong sell&#34; rating in a report issued on Monday,Zacks.com reports.</p><div><p><span></span><span>Get <strong>Organon &amp; Co.</strong> alerts:</span></p></div><ul><li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li></ul><p>Several other research firms also recently commented on OGN. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a research note on Wednesday, October 8th. Piper Sandler cut Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 price target on the stock. in a research report on Monday, October 27th. Morgan Stanley decreased their price objective on Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating for the company in a report on Tuesday, November 11th. Finally, JPMorgan Chase &amp; Co. dropped their price objective on shares of Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 11th. One investment analyst  has rated the stock with a Strong Buy rating, two have assigned  a Hold rating and four have assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Reduce&#34; and a consensus price target of $8.38.</p><p><b>Get Our Latest Analysis on Organon &amp; Co.</b></p><h2>Organon &amp; Co. Trading Down 5.0%</h2><ul><li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li></ul><p>NYSE OGN opened at $6.93 on Monday. The business's fifty day moving average is $8.15 and its 200-day moving average is $9.20. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 3.61, a PEG ratio of 1.56 and a beta of 0.57. Organon &amp; Co. has a one year low of $6.18 and a one year high of $17.23. </p><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.08. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon &amp; Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same quarter last year, the company posted $1.38 earnings per share.  Equities research analysts predict that  Organon &amp; Co. will post 3.68 EPS for the current year. </p><h2>Hedge Funds Weigh In On Organon &amp; Co.</h2><p>A number of institutional investors have recently added to or reduced their stakes in the business. Ransom Advisory Ltd bought a new stake in shares of  Organon &amp; Co. during the 1st quarter valued at about $32,000.  Hanson &amp; Doremus Investment Management bought a new position in shares of  Organon &amp; Co. in the second quarter worth approximately $26,000.  Hantz Financial Services Inc. raised its stake in  Organon &amp; Co. by 293.8% in the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company's stock valued at $26,000 after purchasing an additional 1,995 shares in the last quarter.  Foster Dykema Cabot &amp; Partners LLC bought a new stake in  Organon &amp; Co. during the third quarter valued at approximately $29,000.  Finally, Brooklyn Investment Group grew its stake in  Organon &amp; Co. by 1,012.3% in the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock worth $46,000 after buying an additional 2,794 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors. </p><h2>Organon &amp; Co. Company Profile</h2> (Get Free Report)<p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p><h2>Read More</h2><ul><li>Five stocks we like better than Organon &amp; Co.</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Insiders Are Selling These 3 Stocks—Here’s Why</li><li>Top Stocks Investing in 5G Technology</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2><p>Before you consider Organon &amp; Co., you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p><p>While Organon &amp; Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Barclays upgraded Organon & Co. to a "strong sell" rating, while other firms have varied ratings, including "sell" and "underweight." The stock opened at $6.93, with a market cap of $1.80 billion. Organon reported $1.01 EPS, beating estimates. Institutional investors are adjusting stakes, with 77.43% ownership. Organon is a pharmaceutical company focused on women's health and biosimilars.</p>

Organon & Co. (NYSE:OGN) Stock Rating Upgraded by Barclays